Status:
RECRUITING
Strategies to AchieVe Viral Suppression for Youth With HIV
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Human Immunodeficiency Virus (HIV) Infection
Eligibility:
All Genders
12-30 years
Phase:
NA
Brief Summary
Although there have been advances in antiretroviral treatment (ART) for HIV, adolescents and young adults living with HIV (AHIV) continue to have disparate HIV outcomes particularly viral suppression ...
Detailed Description
Adolescents and young adults (AHIV) ages 12-30 years have disproportionately poorer outcomes across the HIV care continuum, including lower rates of adherence to oral ART (oART) and viral suppression ...
Eligibility Criteria
Inclusion
- prescribed ART,
- willing to sign informed consent (including communication with one's primary HIV provider)
Exclusion
- Relevant drug resistance mutations (per medical record) that compromises activity of Cabotegravir (CBG) + rilpivirine (RPV)
- disallowed medications,
- pregnancy.
- Mental health, cognitive, or behavioral dysfunction that in the opinion of the site PI would impair participation;
- severe illness/hospitalization at the time of enrollment,
- plan to move away in the next 12 months.
Key Trial Info
Start Date :
November 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2028
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT06886971
Start Date
November 10 2024
End Date
July 31 2028
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287